NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
AllVascular
University of California, San Diego
ImmunityBio, Inc.
Eisai Inc.
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Agennix
University of Michigan Rogel Cancer Center